Levi & Korsinsky, LLP notifies investors in Verve Therapeutics, Inc. (“Verve Therapeutics” or the “Company”) (NASDAQ: VERV) of a class action securities lawsuit.
https://mma.prnewswire.com/media/2280334/Levi_and_Korsinsky_Logo.jpg
CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Verve Therapeutics investors who were adversely affected by alleged securities fraud between August 9, 2022 and April 1, 2024. Follow the link below to get more information and be contacted by a member of our team:
VERVinvestors may also contact Joseph E. Levi, Esq. via email atjlevi@levikorsinsky.comor by telephone at (212) 363-7500.
CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) defendants did not fully disclose the circumstances under which the Heart-1 Phase 1b clinical trial of VERVE-101, its investigational gene editing medicine, would be halted; (2) defendants overstated the potential benefits of its proprietary lipid nanoparticle delivery system; and (3) as a result, defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.
WHAT’S NEXT? If you suffered a loss in Verve Therapeutics during the relevant time frame, you have until October 28, 2024to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.
WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services’ Top 50 Report as one of the top securities litigation firms in the United States.
CONTACT:Levi & Korsinsky, LLP Joseph E. Levi, Esq.Ed Korsinsky, Esq.33 Whitehall Street, 17th FloorNew York, NY 10004jlevi@levikorsinsky.comTel: (212) 363-7500Fax: (212) 363-7171www.zlk.com
https://c212.net/c/img/favicon.png?sn=NY16923&sd=2024-09-27
View original content to download multimedia:https://www.prnewswire.com/news-releases/shareholders-that-lost-money-on-verve-therapeutics-incverv-should-contact-levi–korsinsky-about-pending-class-action—verv-302260206.html
SOURCE Levi & Korsinsky, LLP
https://rt.newswire.ca/rt.gif?NewsItemId=NY16923&Transmission_Id=202409270545PR_NEWS_USPR_____NY16923&DateId=20240927
COMTEX_458225836/1005/2024-09-27T05:45:36